X

Trial Profile

An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tildrakizumab (Primary)
Indications Psoriatic arthritis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms INSPIRE LTE
Sponsors Sun Pharmaceutical Industries

Most Recent Events

02 Nov 2023 Status changed from active, no longer recruiting to recruiting.
05 Aug 2022 Status changed from recruiting to active, no longer recruiting.
08 Jul 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com